News
Qurgen real-time updates on corporate news, industry trends and exciting events, witnessing every step of growth.
News
Qurgen announced that a late-stage of ocular melanoma patient from the ongoing Qurgen clinical trial showed no detection of the melanoma driver BAP1 gene mutations in the blood and biopsy tissue samples before (> 70.0% mutation) and after a 9-month SON-DP treatment (mutation not detectable). The SON-DP treatment leads to cancer driver gene mutation-free in the converted tissues. Similar phenomenon has also observed for other driver gene mutations such as KRAS and p53 of different cancer types including colorectal cancer patients.
Dr. Chai Yan officially Joined Qurgen/Fuent (The Qurgen’s China subsidiary) as Senior Vice President of Business Development of Qurgen and the CEO of Suzhou Fuent Pharmaceutics. Also, he serves the Board Secretary to Accelerate the Company’s Strategic Advancement.
Qurgen completed the annual physical examination of five Cynomolgus monkeys (three males and two females) that had received 12 repeated high-dose of SON-DP within a 28-day period eight years ago. No evidence of teratoma formation or tumor development has been observed from these animals in this long-term toxicity study of SON-DP in primates.
Qurgen had successfully manufactured two lots of GMP-manufactured SON-DP anti-cancer drugs that met FDA/CDE protein drug quality standard. Both lots of SON-DP will be used in the US and China Phase I clinical trials.
A patient with non-small cell lung cancer (NSCLC) enrolled in Qurgen’s US Phase 1 clinical trial achieved a complete response (CR) after received SON-DP treatment for three months. As of March 2026, a 14-month follow-up demonstrated that the patient remained tumor-free status.
The China CDE officially approved the IND application of SON-DP Phase I study, submitted by Fuent Pharmaceutcal Co., Ltd. (Qurgen’s China subsidiary), with the CDE acceptance number: CXSL2400508.
Prof Jianjun Wang was invited to attend Tigermed's ASCO Pre-Event Webinar as a Speaker to present Qurgen’s breakthrough cell converting cancer therapy and the recent progress of its Phase I clinical trial.
No infusion related reactions (IRRs) were observed in patients enrolled in the ongoing Qurgen Clinical trial using a 48-hour continuous infusion pump. This modified drug infusion regimen significantly enhanced the safety of SON-DP treatment.
Qurgen reported that numbers of patients with advanced solid tumors had received low-dose SON-DP treatment (2-4.5 mg/kg) for over 18 months. Sustained tumor reduction was observed throughout the 18-month treatment period in some of these patients. In addition, no teratoma formation has been detected in any of the patients. These founding support a favorable safety profile of SON-DP based cellular converting therapy.
Qurgen has expanded the clinical trial of its cell-converting cancer therapy in the following four clinical sites.
Fuent (Qurgen’s China subsidiary) has expanded its cell-converting cancer therapy in the following five clinical sites.
In December 2025, Qurgen Inc. was named one of the World's Top 10 Innovative Companies by MedHealth magazine.